Compare DOMO & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMO | VRCA |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.6M | 137.3M |
| IPO Year | 2018 | 2018 |
| Metric | DOMO | VRCA |
|---|---|---|
| Price | $2.51 | $5.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $10.28 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.7M | 29.4K |
| Earning Date | 05-20-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.92 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $318,857,000.00 | $35,577,000.00 |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $4.72 | $94.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.57 | ★ 370.22 |
| 52 Week Low | $1.84 | $0.52 |
| 52 Week High | $18.49 | $9.82 |
| Indicator | DOMO | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 38.61 | 43.26 |
| Support Level | $2.39 | $5.32 |
| Resistance Level | $4.07 | $6.48 |
| Average True Range (ATR) | 0.39 | 0.48 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 23.68 | 8.33 |
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.